CFAP53

Across TCGA pan-cancer cohorts, CFAP53 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CFAP53 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CFAP53 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CFAP53 expression acts as an unfavorable survival marker.

STAD, ESCA, and SARC are the cancer types where CFAP53 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	IV	0.001	0.544	<.001	24	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	18	view →
SARC	OS	Median	All	0.126	0.860	<.001	12	view →
LUSC	OS	Median	All	0.258	0.677	.005	12	view →
LIHC	OS	Median	All	0.047	0.783	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CFAP53–STAD (OS)

Open the STAD breakdown →